Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiotensin-(1-7) for Cognitive Function in CABG
NCT03252093Phase 2Terminated
- Sponsor
- University of Arizona
- Start
- Jul 2017
- Primary completion
- Nov 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cognitive impairment comparing Angiotensin-(1-7) with Placebo (2 arms). Primary endpoints: Safety and tolerability assessed by adverse events at Day 90 and Change in composite neuropsychological score at Day 90. Started Jul 2017; status: terminated.
02
Drugs
angiotensin-(1-7)
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT03252093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03252093.